{"id":56638,"date":"2023-12-04T13:09:39","date_gmt":"2023-12-04T13:09:39","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=114871"},"modified":"2023-12-04T13:09:39","modified_gmt":"2023-12-04T13:09:39","slug":"zenas-biopharma-renforce-sa-direction-avec-la-nomination-de-jennifer-fox-en-tant-que-chief-business-officer-et-chief-financial-officer-et-de-tanya-fischer-m-d-phd-en-tant-que-head-of-rd-et-c","status":"publish","type":"post","link":"https:\/\/timessouthafrica.com\/zenas-biopharma-renforce-sa-direction-avec-la-nomination-de-jennifer-fox-en-tant-que-chief-business-officer-et-chief-financial-officer-et-de-tanya-fischer-m-d-phd-en-tant-que-head-of-rd-et-c\/","title":{"rendered":"Zenas BioPharma renforce sa direction avec la nomination de Jennifer Fox en tant que Chief Business Officer et Chief Financial Officer et de Tanya Fischer, M.D., PhD., en tant que Head of R&D et Chief Medical Officer"},"content":{"rendered":"
\n

Le renforcement du leadership strat\u00e9gique et op\u00e9rationnel permet \u00e0 Zenas de se d\u00e9velopper et les essais cliniques en phase avanc\u00e9e sur l\u2019ob\u00e9x\u00e9limab progressent, pour de multiples indications potentielles dans l\u2019I&I<\/h4>\n

WALTHAM, Massachusetts, 04 d\u00e9c. 2023 (GLOBE NEWSWIRE) — Zenas\u00a0BioPharma, un laboratoire biopharmaceutique d\u2019envergure mondiale d\u00e9termin\u00e9 \u00e0 devenir un leader dans le d\u00e9veloppement et la commercialisation de traitements dans les domaines de l\u2019inflammation et de l\u2019immunologie (\u00ab\u00a0I&I\u00a0\u00bb), a annonc\u00e9 aujourd\u2019hui la nomination de Jennifer\u00a0Fox aux postes de Chief Business Officer<\/em> (directrice g\u00e9n\u00e9rale) et de Chief Financial Officer<\/em> (directrice financi\u00e8re), ainsi que de Tanya\u00a0Fischer, M.D., PhD., en tant que Head of Research and Development<\/em> (directrice recherche et du d\u00e9veloppement) et Chief Medical Officer<\/em> (directrice m\u00e9dicale).<\/p>\n

\u00ab\u00a0Nous sommes ravis d\u2019accueillir Tanya et Jen dans notre \u00e9quipe de direction\u00a0\u00bb, a d\u00e9clar\u00e9 Lonnie\u00a0Moulder, fondateur et pr\u00e9sident-directeur g\u00e9n\u00e9ral de Zenas\u00a0BioPharma. \u00ab\u00a0Tanya est m\u00e9decin et scientifique, dot\u00e9e d\u2019une longue exp\u00e9rience, et Jen est une dirigeante chevronn\u00e9e dans le domaine de la finance dans les soins de sant\u00e9 et du d\u00e9veloppement des entreprises. Avec leurs dizaines d\u2019ann\u00e9es d\u2019exp\u00e9rience \u00e0 des postes de direction au sein de l\u2019industrie, elles seront toutes deux un atout inestimable pour Zenas \u00e0 l\u2019entame de notre prochaine phase de croissance, en faisant progresser de multiples programmes mondiaux en phase finale de d\u00e9veloppement clinique, avec pour objectif de fournir des traitements diff\u00e9renci\u00e9s dans les domaines de l\u2019I&I aux patients qui en ont besoin dans le monde entier.\u00a0\u00bb<\/p>\n

Jennifer\u00a0Fox est une dirigeante exp\u00e9riment\u00e9e dans le domaine de la finance et du d\u00e9veloppement d\u2019entreprise. Elle se targue d\u2019un palmar\u00e8s impressionnant en mati\u00e8re de finance d\u2019entreprise et de banque d\u2019investissement dans les soins de sant\u00e9, conseillant de nombreuses entreprises priv\u00e9es et publiques en strat\u00e9gie, financement et fusions-acquisitions. Avant de rejoindre Zenas, Jennnifer\u00a0Fox a occup\u00e9 le poste de Chief Financial Officer<\/em> (directrice financi\u00e8re) chez Nuvation\u00a0Bio, une soci\u00e9t\u00e9 de biotechnologie cot\u00e9e en Bourse. Auparavant, elle a \u00e9t\u00e9 Managing Director<\/em> (directrice g\u00e9n\u00e9rale) et Co-Head of North America Healthcare Corporate and Investment Banking Group<\/em> (co-responsable du groupe de banque d\u2019investissement et d\u2019entreprise dans les soins de sant\u00e9, Am\u00e9rique du Nord) chez CitiGroup. Avant de rejoindre CitiGroup, Jennifer\u00a0Fox a occup\u00e9 des postes de direction dans le domaine de la banque d\u2019investissement \u00e0 la Deutsche\u00a0Bank, \u00e0 la Bear\u00a0Stearns, \u00e0 la Bank\u00a0of\u00a0America et chez Prudential\u00a0Securities. Elle est titulaire d\u2019une licence en finance et en marketing d\u00e9livr\u00e9e par le Manhattan\u00a0College.<\/p>\n

Le Dr<\/sup>\u00a0Fischer est m\u00e9decin et scientifique. Elle s\u2019est forg\u00e9e une grande exp\u00e9rience dans le monde universitaire et dans des laboratoires pharmaceutiques et des soci\u00e9t\u00e9s de biotechnologie, en dirigeant des programmes de recherche et de d\u00e9veloppement de stade pr\u00e9coce et avanc\u00e9 dans de nombreux domaines th\u00e9rapeutiques, notamment la neurologie et les maladies rares. Avant de rejoindre Zenas, elle \u00e9tait Chief Development Officer<\/em> (directrice du d\u00e9veloppement) et Head of Translational Medicine<\/em> (directrice de la m\u00e9decine translationnelle) chez Biohaven, un laboratoire biopharmaceutique cot\u00e9 en Bourse. Tanya\u00a0Fischer a commenc\u00e9 sa carri\u00e8re dans l\u2019industrie chez Bristol\u00a0Myers\u00a0Squibb et a occup\u00e9 des postes de direction en R&D, avec de plus en plus de responsabilit\u00e9s, chez EMD-Serono, Sanofi-Genzyme et Alnylam. Elle est neurologue et a \u00e9t\u00e9 professeure \u00e0 l\u2019\u00e9cole de m\u00e9decine de l\u2019universit\u00e9 de Yale au terme de son internat en neurologie \u00e0 l\u2019h\u00f4pital Yale\u00a0New\u00a0Haven. Elle est titulaire d\u2019un doctorat en m\u00e9decine et d\u2019un doctorat en sciences de l\u2019Universit\u00e9 de m\u00e9decine et dentisterie du New\u00a0Jersey (de la Robert\u00a0Wood\u00a0Johnson\u00a0Medical\u00a0School en m\u00e9decine et de l\u2019Universit\u00e9\u00a0Rutgers en sciences). Elle a en outre re\u00e7u la prestigieuse Presidential Early Career Award for Scientists and Engineers<\/em> (PECASE).<\/p>\n

\u00c0 propos de Zenas\u00a0BioPharma<\/strong><\/p>\n

Zenas\u00a0BioPharma est un laboratoire biopharmaceutique d\u2019envergure mondiale d\u00e9termin\u00e9 \u00e0 devenir un leader dans le d\u00e9veloppement et la commercialisation de traitements dans les domaines de l\u2019inflammation et de l\u2019immunologie (\u00ab\u00a0I&I\u00a0\u00bb) pour les patients qui en ont besoin dans le monde entier. Avec des capacit\u00e9s de d\u00e9veloppement et des op\u00e9rations cliniques aux quatre coins de la plan\u00e8te, Zenas fait progresser un portefeuille de traitements de maladies auto-immunes potentiellement diff\u00e9renci\u00e9s dans des domaines o\u00f9 les besoins m\u00e9dicaux ne sont pas satisfaits. Notre \u00e9quipe de direction exp\u00e9riment\u00e9e et notre r\u00e9seau de partenaires commerciaux stimulent l\u2019excellence op\u00e9rationnelle, afin d\u2019apporter des traitements potentiellement transformateurs dans l\u2019optique d\u2019am\u00e9liorer la qualit\u00e9 de vie des personnes atteintes de maladies rares et auto-immunes. Pour tout compl\u00e9ment d\u2019information sur Zenas\u00a0BioPharma, veuillez consulter le site www.zenasbio.com<\/u><\/a> et nous suivre sur Twitter \u00e0 l\u2019adresse @ZenasBioPharma<\/u><\/a> et sur LinkedIn<\/u><\/a>.<\/p>\n

\u00c0 propos de l\u2019ob\u00e9x\u00e9limab<\/strong><\/p>\n

L\u2019ob\u00e9x\u00e9limab est un anticorps monoclonal, humanis\u00e9, non cytolytique, bifonctionnel et exp\u00e9rimental de phase\u00a03, qui imite l\u2019action de complexes antig\u00e8ne-anticorps en liant l\u2019antig\u00e8ne CD19 et le r\u00e9cepteur Fc\u03b3RIIb afin d\u2019inhiber l\u2019activit\u00e9 des lymphocytes\u00a0B. Dans plusieurs \u00e9tudes cliniques de stade pr\u00e9coce, notamment sur diverses maladies auto-immunes, 198\u00a0sujets ont \u00e9t\u00e9 trait\u00e9s avec l\u2019ob\u00e9x\u00e9limab. Dans le cadre de ces \u00e9tudes cliniques, l\u2019ob\u00e9x\u00e9limab a d\u00e9montr\u00e9 une inhibition de la fonction des lymphocytes\u00a0B sans les \u00e9puiser, donnant lieu \u00e0 un effet th\u00e9rapeutique encourageant chez les patients atteints de diverses maladies auto-immunes. Zenas a acquis des droits mondiaux exclusifs sur l\u2019ob\u00e9x\u00e9limab aupr\u00e8s de Xencor,\u00a0Inc. L\u2019ob\u00e9x\u00e9limab fait actuellement l\u2019objet d\u2019une \u00e9tude clinique mondiale de phase\u00a03 portant sur des patients atteints de maladies li\u00e9es aux IgG4 et d\u2019une \u00e9tude mondiale de phase\u00a02\/3 portant sur des patients atteints d\u2019an\u00e9mie h\u00e9molytique auto-immune (\u00ab\u00a0AHAI\u00a0\u00bb) \u00e0 auto-anticorps \u00ab\u00a0chauds\u00a0\u00bb. Le d\u00e9veloppement clinique de l\u2019ob\u00e9x\u00e9limab pour le traitement de la scl\u00e9rose en plaques et du lupus \u00e9ryth\u00e9mateux syst\u00e9mique est en cours d\u2019\u00e9valuation.<\/p>\n

Davantage d\u2019informations sur l\u2019\u00e9tude de phase\u00a03 (INDIGO) pour le traitement de la maladie li\u00e9e aux IgG4 sont disponibles sur clinicaltrials.gov<\/a>\u00a0: NCT05662241. Davantage d\u2019informations sur l\u2019\u00e9tude de phase\u00a03 (SApHiAre) pour le traitement de l\u2019AHAI \u00e0 auto-anticorps \u00ab\u00a0chauds\u00a0\u00bb sont disponibles sur clinicaltrials.gov<\/a> : NCT05786573.<\/p>\n

Contact investisseurs et m\u00e9dias\u00a0:\r\nJoe\u00a0Farmer, pr\u00e9sident et directeur de l\u2019exploitation\r\nZenas\u00a0BioPharma\r\nIR@zenasbio.com<\/a><\/pre>\n
GlobeNewswire Distribution ID 8988518<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"
Le renforcement du leadership strat\u00e9gique et op\u00e9rationnel permet \u00e0 Zenas de se d\u00e9velopper et les essais cliniques en phase avanc\u00e9e sur l\u2019ob\u00e9x\u00e9limab progressent, pour de multiples indications potentielles dans l\u2019I&I WALTHAM, Massachusetts, 04 d\u00e9c. 2023 (GLOBE NEWSWIRE) \u2014 Zenas\u00a0BioPharma, un laboratoire biopharmaceutique d\u2019envergure mondiale d\u00e9termin\u00e9 \u00e0 devenir un leader dans le d\u00e9veloppement et la commercialisation [\u2026]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[35],"tags":[10,12],"yoast_head":"\nZenas BioPharma renforce sa direction avec la nomination de Jennifer Fox en tant que Chief Business Officer et Chief Financial Officer et de Tanya Fischer, M.D., PhD., en tant que Head of R&D et Chief Medical Officer - Times South Africa<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/timessouthafrica.com\/zenas-biopharma-renforce-sa-direction-avec-la-nomination-de-jennifer-fox-en-tant-que-chief-business-officer-et-chief-financial-officer-et-de-tanya-fischer-m-d-phd-en-tant-que-head-of-rd-et-c\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zenas BioPharma renforce sa direction avec la nomination de Jennifer Fox en tant que Chief Business Officer et Chief Financial Officer et de Tanya Fischer, M.D., PhD., en tant que Head of R&D et Chief Medical Officer - Times South Africa\" \/>\n<meta property=\"og:description\" content=\"Le renforcement du leadership strat\u00e9gique et op\u00e9rationnel permet \u00e0 Zenas de se d\u00e9velopper et les essais cliniques en phase avanc\u00e9e sur l\u2019ob\u00e9x\u00e9limab progressent, pour de multiples indications potentielles dans l\u2019I&I WALTHAM, Massachusetts, 04 d\u00e9c. 2023 (GLOBE NEWSWIRE) \u2014 Zenas\u00a0BioPharma, un laboratoire biopharmaceutique d\u2019envergure mondiale d\u00e9termin\u00e9 \u00e0 devenir un leader dans le d\u00e9veloppement et la commercialisation [\u2026]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/timessouthafrica.com\/zenas-biopharma-renforce-sa-direction-avec-la-nomination-de-jennifer-fox-en-tant-que-chief-business-officer-et-chief-financial-officer-et-de-tanya-fischer-m-d-phd-en-tant-que-head-of-rd-et-c\/\" \/>\n<meta property=\"og:site_name\" content=\"Times South Africa\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-04T13:09:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ci5.googleusercontent.com\/proxy\/c9ia8ApSoli9tg-u5tTiiv03R_ZGr9eVEYz6cr6v_ThxOBwsBq46tTVp6r3hfSQ1RKOfqdRdTEjMEku3HPWxMk9rn3DCWrDQgLbjyCZ-ba9fn-q6ThBt2SPEIi0o3pgin1KmOfiPEHWNyPSKdwTGdWC1gd6r3NrwEwZkPGLThbcpURuOHsV7wvVbgWPl2yhxHYnLFg=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/MWZhZDMyNGUtOTE0OC00NzBhLTljODAtYTAwODE2NGM2ZWFlLTEyMTkzNDg=\/tiny\/Zenas-BioPharma-USA-LLC.png\" \/>\n<meta name=\"author\" content=\"TSA\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"TSA\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/timessouthafrica.com\/zenas-biopharma-renforce-sa-direction-avec-la-nomination-de-jennifer-fox-en-tant-que-chief-business-officer-et-chief-financial-officer-et-de-tanya-fischer-m-d-phd-en-tant-que-head-of-rd-et-c\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/timessouthafrica.com\/zenas-biopharma-renforce-sa-direction-avec-la-nomination-de-jennifer-fox-en-tant-que-chief-business-officer-et-chief-financial-officer-et-de-tanya-fischer-m-d-phd-en-tant-que-head-of-rd-et-c\/\"},\"author\":{\"name\":\"TSA\",\"@id\":\"https:\/\/timessouthafrica.com\/#\/schema\/person\/3b17cd6e128204bbcfbfa7ed541048b1\"},\"headline\":\"Zenas BioPharma renforce sa direction avec la nomination de Jennifer Fox en tant que Chief Business Officer et Chief Financial Officer et de Tanya Fischer, M.D., PhD., en tant que Head of R&D et Chief Medical Officer\",\"datePublished\":\"2023-12-04T13:09:39+00:00\",\"dateModified\":\"2023-12-04T13:09:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/timessouthafrica.com\/zenas-biopharma-renforce-sa-direction-avec-la-nomination-de-jennifer-fox-en-tant-que-chief-business-officer-et-chief-financial-officer-et-de-tanya-fischer-m-d-phd-en-tant-que-head-of-rd-et-c\/\"},\"wordCount\":1148,\"publisher\":{\"@id\":\"https:\/\/timessouthafrica.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/timessouthafrica.com\/zenas-biopharma-renforce-sa-direction-avec-la-nomination-de-jennifer-fox-en-tant-que-chief-business-officer-et-chief-financial-officer-et-de-tanya-fischer-m-d-phd-en-tant-que-head-of-rd-et-c\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ci5.googleusercontent.com\/proxy\/c9ia8ApSoli9tg-u5tTiiv03R_ZGr9eVEYz6cr6v_ThxOBwsBq46tTVp6r3hfSQ1RKOfqdRdTEjMEku3HPWxMk9rn3DCWrDQgLbjyCZ-ba9fn-q6ThBt2SPEIi0o3pgin1KmOfiPEHWNyPSKdwTGdWC1gd6r3NrwEwZkPGLThbcpURuOHsV7wvVbgWPl2yhxHYnLFg=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/MWZhZDMyNGUtOTE0OC00NzBhLTljODAtYTAwODE2NGM2ZWFlLTEyMTkzNDg=\/tiny\/Zenas-BioPharma-USA-LLC.png\",\"keywords\":[\"Africa\",\"South Africa\"],\"articleSection\":[\"Press Releases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/timessouthafrica.com\/zenas-biopharma-renforce-sa-direction-avec-la-nomination-de-jennifer-fox-en-tant-que-chief-business-officer-et-chief-financial-officer-et-de-tanya-fischer-m-d-phd-en-tant-que-head-of-rd-et-c\/\",\"url\":\"https:\/\/timessouthafrica.com\/zenas-biopharma-renforce-sa-direction-avec-la-nomination-de-jennifer-fox-en-tant-que-chief-business-officer-et-chief-financial-officer-et-de-tanya-fischer-m-d-phd-en-tant-que-head-of-rd-et-c\/\",\"name\":\"Zenas BioPharma renforce sa direction avec la nomination de Jennifer Fox en tant que Chief Business Officer et Chief Financial Officer et de Tanya Fischer, M.D., PhD., en tant que Head of R&D et Chief Medical Officer - Times South Africa\",\"isPartOf\":{\"@id\":\"https:\/\/timessouthafrica.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/timessouthafrica.com\/zenas-biopharma-renforce-sa-direction-avec-la-nomination-de-jennifer-fox-en-tant-que-chief-business-officer-et-chief-financial-officer-et-de-tanya-fischer-m-d-phd-en-tant-que-head-of-rd-et-c\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/timessouthafrica.com\/zenas-biopharma-renforce-sa-direction-avec-la-nomination-de-jennifer-fox-en-tant-que-chief-business-officer-et-chief-financial-officer-et-de-tanya-fischer-m-d-phd-en-tant-que-head-of-rd-et-c\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ci5.googleusercontent.com\/proxy\/c9ia8ApSoli9tg-u5tTiiv03R_ZGr9eVEYz6cr6v_ThxOBwsBq46tTVp6r3hfSQ1RKOfqdRdTEjMEku3HPWxMk9rn3DCWrDQgLbjyCZ-ba9fn-q6ThBt2SPEIi0o3pgin1KmOfiPEHWNyPSKdwTGdWC1gd6r3NrwEwZkPGLThbcpURuOHsV7wvVbgWPl2yhxHYnLFg=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/MWZhZDMyNGUtOTE0OC00NzBhLTljODAtYTAwODE2NGM2ZWFlLTEyMTkzNDg=\/tiny\/Zenas-BioPharma-USA-LLC.png\",\"datePublished\":\"2023-12-04T13:09:39+00:00\",\"dateModified\":\"2023-12-04T13:09:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/timessouthafrica.com\/zenas-biopharma-renforce-sa-direction-avec-la-nomination-de-jennifer-fox-en-tant-que-chief-business-officer-et-chief-financial-officer-et-de-tanya-fischer-m-d-phd-en-tant-que-head-of-rd-et-c\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/timessouthafrica.com\/zenas-biopharma-renforce-sa-direction-avec-la-nomination-de-jennifer-fox-en-tant-que-chief-business-officer-et-chief-financial-officer-et-de-tanya-fischer-m-d-phd-en-tant-que-head-of-rd-et-c\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/timessouthafrica.com\/zenas-biopharma-renforce-sa-direction-avec-la-nomination-de-jennifer-fox-en-tant-que-chief-business-officer-et-chief-financial-officer-et-de-tanya-fischer-m-d-phd-en-tant-que-head-of-rd-et-c\/#primaryimage\",\"url\":\"https:\/\/ci5.googleusercontent.com\/proxy\/c9ia8ApSoli9tg-u5tTiiv03R_ZGr9eVEYz6cr6v_ThxOBwsBq46tTVp6r3hfSQ1RKOfqdRdTEjMEku3HPWxMk9rn3DCWrDQgLbjyCZ-ba9fn-q6ThBt2SPEIi0o3pgin1KmOfiPEHWNyPSKdwTGdWC1gd6r3NrwEwZkPGLThbcpURuOHsV7wvVbgWPl2yhxHYnLFg=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/MWZhZDMyNGUtOTE0OC00NzBhLTljODAtYTAwODE2NGM2ZWFlLTEyMTkzNDg=\/tiny\/Zenas-BioPharma-USA-LLC.png\",\"contentUrl\":\"https:\/\/ci5.googleusercontent.com\/proxy\/c9ia8ApSoli9tg-u5tTiiv03R_ZGr9eVEYz6cr6v_ThxOBwsBq46tTVp6r3hfSQ1RKOfqdRdTEjMEku3HPWxMk9rn3DCWrDQgLbjyCZ-ba9fn-q6ThBt2SPEIi0o3pgin1KmOfiPEHWNyPSKdwTGdWC1gd6r3NrwEwZkPGLThbcpURuOHsV7wvVbgWPl2yhxHYnLFg=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/MWZhZDMyNGUtOTE0OC00NzBhLTljODAtYTAwODE2NGM2ZWFlLTEyMTkzNDg=\/tiny\/Zenas-BioPharma-USA-LLC.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/timessouthafrica.com\/zenas-biopharma-renforce-sa-direction-avec-la-nomination-de-jennifer-fox-en-tant-que-chief-business-officer-et-chief-financial-officer-et-de-tanya-fischer-m-d-phd-en-tant-que-head-of-rd-et-c\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/timessouthafrica.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zenas BioPharma renforce sa direction avec la nomination de Jennifer Fox en tant que Chief Business Officer et Chief Financial Officer et de Tanya Fischer, M.D., PhD., en tant que Head of R&D et Chief Medical Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/timessouthafrica.com\/#website\",\"url\":\"https:\/\/timessouthafrica.com\/\",\"name\":\"Times South Africa\",\"description\":\"Where Africa Comes First\",\"publisher\":{\"@id\":\"https:\/\/timessouthafrica.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/timessouthafrica.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/timessouthafrica.com\/#organization\",\"name\":\"Times South Africa\",\"url\":\"https:\/\/timessouthafrica.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/timessouthafrica.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/timessouthafrica.com\/wp-content\/uploads\/2023\/09\/22.png\",\"contentUrl\":\"https:\/\/timessouthafrica.com\/wp-content\/uploads\/2023\/09\/22.png\",\"width\":200,\"height\":57,\"caption\":\"Times South Africa\"},\"image\":{\"@id\":\"https:\/\/timessouthafrica.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/timessouthafrica.com\/#\/schema\/person\/3b17cd6e128204bbcfbfa7ed541048b1\",\"name\":\"TSA\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/timessouthafrica.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g\",\"caption\":\"TSA\"},\"url\":\"https:\/\/timessouthafrica.com\/author\/tsa\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Zenas BioPharma renforce sa direction avec la nomination de Jennifer Fox en tant que Chief Business Officer et Chief Financial Officer et de Tanya Fischer, M.D., PhD., en tant que Head of R&D et Chief Medical Officer - Times South Africa","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/timessouthafrica.com\/zenas-biopharma-renforce-sa-direction-avec-la-nomination-de-jennifer-fox-en-tant-que-chief-business-officer-et-chief-financial-officer-et-de-tanya-fischer-m-d-phd-en-tant-que-head-of-rd-et-c\/","og_locale":"en_US","og_type":"article","og_title":"Zenas BioPharma renforce sa direction avec la nomination de Jennifer Fox en tant que Chief Business Officer et Chief Financial Officer et de Tanya Fischer, M.D., PhD., en tant que Head of R&D et Chief Medical Officer - Times South Africa","og_description":"Le renforcement du leadership strat\u00e9gique et op\u00e9rationnel permet \u00e0 Zenas de se d\u00e9velopper et les essais cliniques en phase avanc\u00e9e sur l\u2019ob\u00e9x\u00e9limab progressent, pour de multiples indications potentielles dans l\u2019I&I WALTHAM, Massachusetts, 04 d\u00e9c. 2023 (GLOBE NEWSWIRE) \u2014 Zenas\u00a0BioPharma, un laboratoire biopharmaceutique d\u2019envergure mondiale d\u00e9termin\u00e9 \u00e0 devenir un leader dans le d\u00e9veloppement et la commercialisation [\u2026]","og_url":"https:\/\/timessouthafrica.com\/zenas-biopharma-renforce-sa-direction-avec-la-nomination-de-jennifer-fox-en-tant-que-chief-business-officer-et-chief-financial-officer-et-de-tanya-fischer-m-d-phd-en-tant-que-head-of-rd-et-c\/","og_site_name":"Times South Africa","article_published_time":"2023-12-04T13:09:39+00:00","og_image":[{"url":"https:\/\/ci5.googleusercontent.com\/proxy\/c9ia8ApSoli9tg-u5tTiiv03R_ZGr9eVEYz6cr6v_ThxOBwsBq46tTVp6r3hfSQ1RKOfqdRdTEjMEku3HPWxMk9rn3DCWrDQgLbjyCZ-ba9fn-q6ThBt2SPEIi0o3pgin1KmOfiPEHWNyPSKdwTGdWC1gd6r3NrwEwZkPGLThbcpURuOHsV7wvVbgWPl2yhxHYnLFg=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/MWZhZDMyNGUtOTE0OC00NzBhLTljODAtYTAwODE2NGM2ZWFlLTEyMTkzNDg=\/tiny\/Zenas-BioPharma-USA-LLC.png"}],"author":"TSA","twitter_card":"summary_large_image","twitter_misc":{"Written by":"TSA","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/timessouthafrica.com\/zenas-biopharma-renforce-sa-direction-avec-la-nomination-de-jennifer-fox-en-tant-que-chief-business-officer-et-chief-financial-officer-et-de-tanya-fischer-m-d-phd-en-tant-que-head-of-rd-et-c\/#article","isPartOf":{"@id":"https:\/\/timessouthafrica.com\/zenas-biopharma-renforce-sa-direction-avec-la-nomination-de-jennifer-fox-en-tant-que-chief-business-officer-et-chief-financial-officer-et-de-tanya-fischer-m-d-phd-en-tant-que-head-of-rd-et-c\/"},"author":{"name":"TSA","@id":"https:\/\/timessouthafrica.com\/#\/schema\/person\/3b17cd6e128204bbcfbfa7ed541048b1"},"headline":"Zenas BioPharma renforce sa direction avec la nomination de Jennifer Fox en tant que Chief Business Officer et Chief Financial Officer et de Tanya Fischer, M.D., PhD., en tant que Head of R&D et Chief Medical Officer","datePublished":"2023-12-04T13:09:39+00:00","dateModified":"2023-12-04T13:09:39+00:00","mainEntityOfPage":{"@id":"https:\/\/timessouthafrica.com\/zenas-biopharma-renforce-sa-direction-avec-la-nomination-de-jennifer-fox-en-tant-que-chief-business-officer-et-chief-financial-officer-et-de-tanya-fischer-m-d-phd-en-tant-que-head-of-rd-et-c\/"},"wordCount":1148,"publisher":{"@id":"https:\/\/timessouthafrica.com\/#organization"},"image":{"@id":"https:\/\/timessouthafrica.com\/zenas-biopharma-renforce-sa-direction-avec-la-nomination-de-jennifer-fox-en-tant-que-chief-business-officer-et-chief-financial-officer-et-de-tanya-fischer-m-d-phd-en-tant-que-head-of-rd-et-c\/#primaryimage"},"thumbnailUrl":"https:\/\/ci5.googleusercontent.com\/proxy\/c9ia8ApSoli9tg-u5tTiiv03R_ZGr9eVEYz6cr6v_ThxOBwsBq46tTVp6r3hfSQ1RKOfqdRdTEjMEku3HPWxMk9rn3DCWrDQgLbjyCZ-ba9fn-q6ThBt2SPEIi0o3pgin1KmOfiPEHWNyPSKdwTGdWC1gd6r3NrwEwZkPGLThbcpURuOHsV7wvVbgWPl2yhxHYnLFg=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/MWZhZDMyNGUtOTE0OC00NzBhLTljODAtYTAwODE2NGM2ZWFlLTEyMTkzNDg=\/tiny\/Zenas-BioPharma-USA-LLC.png","keywords":["Africa","South Africa"],"articleSection":["Press Releases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/timessouthafrica.com\/zenas-biopharma-renforce-sa-direction-avec-la-nomination-de-jennifer-fox-en-tant-que-chief-business-officer-et-chief-financial-officer-et-de-tanya-fischer-m-d-phd-en-tant-que-head-of-rd-et-c\/","url":"https:\/\/timessouthafrica.com\/zenas-biopharma-renforce-sa-direction-avec-la-nomination-de-jennifer-fox-en-tant-que-chief-business-officer-et-chief-financial-officer-et-de-tanya-fischer-m-d-phd-en-tant-que-head-of-rd-et-c\/","name":"Zenas BioPharma renforce sa direction avec la nomination de Jennifer Fox en tant que Chief Business Officer et Chief Financial Officer et de Tanya Fischer, M.D., PhD., en tant que Head of R&D et Chief Medical Officer - Times South Africa","isPartOf":{"@id":"https:\/\/timessouthafrica.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/timessouthafrica.com\/zenas-biopharma-renforce-sa-direction-avec-la-nomination-de-jennifer-fox-en-tant-que-chief-business-officer-et-chief-financial-officer-et-de-tanya-fischer-m-d-phd-en-tant-que-head-of-rd-et-c\/#primaryimage"},"image":{"@id":"https:\/\/timessouthafrica.com\/zenas-biopharma-renforce-sa-direction-avec-la-nomination-de-jennifer-fox-en-tant-que-chief-business-officer-et-chief-financial-officer-et-de-tanya-fischer-m-d-phd-en-tant-que-head-of-rd-et-c\/#primaryimage"},"thumbnailUrl":"https:\/\/ci5.googleusercontent.com\/proxy\/c9ia8ApSoli9tg-u5tTiiv03R_ZGr9eVEYz6cr6v_ThxOBwsBq46tTVp6r3hfSQ1RKOfqdRdTEjMEku3HPWxMk9rn3DCWrDQgLbjyCZ-ba9fn-q6ThBt2SPEIi0o3pgin1KmOfiPEHWNyPSKdwTGdWC1gd6r3NrwEwZkPGLThbcpURuOHsV7wvVbgWPl2yhxHYnLFg=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/MWZhZDMyNGUtOTE0OC00NzBhLTljODAtYTAwODE2NGM2ZWFlLTEyMTkzNDg=\/tiny\/Zenas-BioPharma-USA-LLC.png","datePublished":"2023-12-04T13:09:39+00:00","dateModified":"2023-12-04T13:09:39+00:00","breadcrumb":{"@id":"https:\/\/timessouthafrica.com\/zenas-biopharma-renforce-sa-direction-avec-la-nomination-de-jennifer-fox-en-tant-que-chief-business-officer-et-chief-financial-officer-et-de-tanya-fischer-m-d-phd-en-tant-que-head-of-rd-et-c\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/timessouthafrica.com\/zenas-biopharma-renforce-sa-direction-avec-la-nomination-de-jennifer-fox-en-tant-que-chief-business-officer-et-chief-financial-officer-et-de-tanya-fischer-m-d-phd-en-tant-que-head-of-rd-et-c\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/timessouthafrica.com\/zenas-biopharma-renforce-sa-direction-avec-la-nomination-de-jennifer-fox-en-tant-que-chief-business-officer-et-chief-financial-officer-et-de-tanya-fischer-m-d-phd-en-tant-que-head-of-rd-et-c\/#primaryimage","url":"https:\/\/ci5.googleusercontent.com\/proxy\/c9ia8ApSoli9tg-u5tTiiv03R_ZGr9eVEYz6cr6v_ThxOBwsBq46tTVp6r3hfSQ1RKOfqdRdTEjMEku3HPWxMk9rn3DCWrDQgLbjyCZ-ba9fn-q6ThBt2SPEIi0o3pgin1KmOfiPEHWNyPSKdwTGdWC1gd6r3NrwEwZkPGLThbcpURuOHsV7wvVbgWPl2yhxHYnLFg=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/MWZhZDMyNGUtOTE0OC00NzBhLTljODAtYTAwODE2NGM2ZWFlLTEyMTkzNDg=\/tiny\/Zenas-BioPharma-USA-LLC.png","contentUrl":"https:\/\/ci5.googleusercontent.com\/proxy\/c9ia8ApSoli9tg-u5tTiiv03R_ZGr9eVEYz6cr6v_ThxOBwsBq46tTVp6r3hfSQ1RKOfqdRdTEjMEku3HPWxMk9rn3DCWrDQgLbjyCZ-ba9fn-q6ThBt2SPEIi0o3pgin1KmOfiPEHWNyPSKdwTGdWC1gd6r3NrwEwZkPGLThbcpURuOHsV7wvVbgWPl2yhxHYnLFg=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/MWZhZDMyNGUtOTE0OC00NzBhLTljODAtYTAwODE2NGM2ZWFlLTEyMTkzNDg=\/tiny\/Zenas-BioPharma-USA-LLC.png"},{"@type":"BreadcrumbList","@id":"https:\/\/timessouthafrica.com\/zenas-biopharma-renforce-sa-direction-avec-la-nomination-de-jennifer-fox-en-tant-que-chief-business-officer-et-chief-financial-officer-et-de-tanya-fischer-m-d-phd-en-tant-que-head-of-rd-et-c\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/timessouthafrica.com\/"},{"@type":"ListItem","position":2,"name":"Zenas BioPharma renforce sa direction avec la nomination de Jennifer Fox en tant que Chief Business Officer et Chief Financial Officer et de Tanya Fischer, M.D., PhD., en tant que Head of R&D et Chief Medical Officer"}]},{"@type":"WebSite","@id":"https:\/\/timessouthafrica.com\/#website","url":"https:\/\/timessouthafrica.com\/","name":"Times South Africa","description":"Where Africa Comes First","publisher":{"@id":"https:\/\/timessouthafrica.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/timessouthafrica.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/timessouthafrica.com\/#organization","name":"Times South Africa","url":"https:\/\/timessouthafrica.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/timessouthafrica.com\/#\/schema\/logo\/image\/","url":"https:\/\/timessouthafrica.com\/wp-content\/uploads\/2023\/09\/22.png","contentUrl":"https:\/\/timessouthafrica.com\/wp-content\/uploads\/2023\/09\/22.png","width":200,"height":57,"caption":"Times South Africa"},"image":{"@id":"https:\/\/timessouthafrica.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/timessouthafrica.com\/#\/schema\/person\/3b17cd6e128204bbcfbfa7ed541048b1","name":"TSA","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/timessouthafrica.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g","caption":"TSA"},"url":"https:\/\/timessouthafrica.com\/author\/tsa\/"}]}},"_links":{"self":[{"href":"https:\/\/timessouthafrica.com\/wp-json\/wp\/v2\/posts\/56638"}],"collection":[{"href":"https:\/\/timessouthafrica.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/timessouthafrica.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/timessouthafrica.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/timessouthafrica.com\/wp-json\/wp\/v2\/comments?post=56638"}],"version-history":[{"count":0,"href":"https:\/\/timessouthafrica.com\/wp-json\/wp\/v2\/posts\/56638\/revisions"}],"wp:attachment":[{"href":"https:\/\/timessouthafrica.com\/wp-json\/wp\/v2\/media?parent=56638"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/timessouthafrica.com\/wp-json\/wp\/v2\/categories?post=56638"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/timessouthafrica.com\/wp-json\/wp\/v2\/tags?post=56638"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}